Research library
Omeros Corporation (OMER): the bull case and the bear case
Omeros Corporation · NASDAQ · Equity · Stock
The synthesis
Strong U.S. commercial traction for Yartemlia is offset by a definitive regulatory rejection for narsoplimab in Europe.
- Accelerating U.S. Commercial Adoption
Yartemlea ordering accounts grew 143% between March and June 2026, reaching 73 unique accounts as the first approved lectin pathway inhibitor.
- Exceptional Product Profitability
The company maintains a 95.8% gross margin, providing significant operating leverage as Yartemlea sales scale following its January 2026 launch.
- Improving Cash Flow Profile
Omeros reported $4.1 million in positive operating cash flow for the June quarter, supported by a $132 million liquidity position as of August 2026.
- Proactive Capital Management
Strategic debt repurchases in July 2026 reduced the 2029 Notes principal to $40.3 million, significantly lowering potential future share dilution.
- Major European Regulatory Setback
The EMA CHMP issued a final negative opinion on narsoplimab for TA-TMA, effectively closing off the European market and ending compassionate-use programs.
- Severe Operational Cash Burn
Despite high gross margins, operating and free cash flow margins remain deeply negative at -189.5% and -178.9% due to heavy R&D and overhead.
- Technical Breakdown of Support
The stock has broken below its 50-day moving average of $18.23 and prior support levels near $17.17, signaling a shift to a short-term bearish trend.
- Single Product Concentration Risk
Following the narsoplimab rejection, Omeros is heavily reliant on Yartemlea, which is in an early commercial stage with fluctuating sales data.
Catalysts
- Q3 Earnings Release Nov 2026
- Yartemlea Formulary Updates Ongoing
- Narsoplimab FDA Strategy Update Near-term
- Share Repurchase Execution Ongoing
Risks
- Regulatory Rejection EMA Final Opinion
- Negative Equity -1.63 D/E Ratio
- Product Concentration Yartemlea Reliance
- Stock Volatility Buyback Impact
What would change the view
The bearish outlook would intensify if Yartemlea account growth plateaus or if the stock fails to hold its 200-day moving average of $13.34. Conversely, a pivot toward a more bullish stance would be supported by a surprise regulatory path forward for narsoplimab in other jurisdictions or sustained quarterly profitability.
Insider activity
Open-market purchases and sales reported by company insiders on SEC Form 4, from EDGAR. Share counts and dates only.
Trailing 3 months: 0 open-market purchases by 0 insiders and 11 sales by 4 insiders. Net selling (Strong — 4 insiders selling).
| Insider | Role | Side | Shares | Trade date | Filing |
|---|---|---|---|---|---|
| Cancelmo Peter B | Officer · VP, General Counsel | Sale | 25,000 | 2026-08-28 | Form 4 |
| Cancelmo Peter B | Officer · VP, General Counsel | Sale | 25,000 | 2026-08-31 | Form 4 |
| Cable Thomas J. | Director | Sale | 15,000 | 2026-08-20 | Form 4 |
| Borges David J. | Officer · VP, Finance & CAO | Sale | 10,000 | 2026-09-22 | Form 4 |
| Borges David J. | Officer · VP, Finance & CAO | Sale | 10,000 | 2026-09-23 | Form 4 |
Sources
- FMP · OMER daily prices and technical indicators Analyst note
- FMP · OMER financial statements (income / balance / cash flow) SEC filing
- SEC EDGAR · OMER full-text filing search SEC filing
- SEC · 4 filed 2026-09-24 SEC filing · 4 · 2026-09-24
- SEC · 144 filed 2026-09-23 SEC filing · 144 · 2026-09-23
- SEC · 144 filed 2026-09-22 SEC filing · 144 · 2026-09-22
- SEC · 4 filed 2026-09-01 SEC filing · 4 · 2026-09-01
- SEC · 144 filed 2026-08-31 SEC filing · 144 · 2026-08-31
- SEC · 144 filed 2026-08-28 SEC filing · 144 · 2026-08-28
- SEC · 4 filed 2026-08-28 SEC filing · 4 · 2026-08-28
- SEC · 144 filed 2026-08-27 SEC filing · 144 · 2026-08-27
- SEC · 144 filed 2026-08-26 SEC filing · 144 · 2026-08-26
- SEC · 4 filed 2026-08-25 SEC filing · 4 · 2026-08-25
- SEC · 4 filed 2026-08-21 SEC filing · 4 · 2026-08-21
- SEC · 144 filed 2026-08-21 SEC filing · 144 · 2026-08-21
- SEC · 144 filed 2026-08-20 SEC filing · 144 · 2026-08-20
- SEC · 4 filed 2026-08-18 SEC filing · 4 · 2026-08-18
- SEC · 3 filed 2026-08-18 SEC filing · 3 · 2026-08-18
- SEC · 4 filed 2026-08-17 SEC filing · 4 · 2026-08-17
- SEC · 144 filed 2026-08-13 SEC filing · 144 · 2026-08-13
- SEC · S-8 filed 2026-08-13 SEC filing · S-8 · 2026-08-13
- SEC · 8-K filed 2026-08-13 (Items 5.02) SEC filing · 8-K · 2026-08-13
- SEC · 10-Q filed 2026-08-12 SEC filing · 10-Q · 2026-08-12
- SEC · 8-K filed 2026-08-12 (Items 2.02, 9.01) SEC filing · 8-K · 2026-08-12
- SEC · SCHEDULE 13G/A filed 2026-07-29 SEC filing · SCHEDULE 13G/A · 2026-07-29
- SEC · 4 filed 2026-07-24 SEC filing · 4 · 2026-07-24
- SEC · 4 filed 2026-07-24 SEC filing · 4 · 2026-07-24
- SEC · 4 filed 2026-07-24 SEC filing · 4 · 2026-07-24
- SEC · 8-K filed 2026-07-20 (Items 8.01) SEC filing · 8-K · 2026-07-20
- Benzinga · Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends News
- Business Wire · Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Applicati News
Read the full analysis in the app
This page publishes the written thesis. The app adds the sections not published here:
- Fundamentals
- Technicals
- News with bull, bear, and neutral tags
- 7-day news sentiment and earnings-call tone
- Forward analyst estimates
- Earnings-call summary
